Patient enrollment has started at sites in the European Union for a global Phase 3 clinical trial evaluating the safety and efficacy of navenibart, an antibody-based therapy designed to prevent swelling attacks in people with hereditary angioedema (HAE). Dubbed ALPHA-ORBIT trial (NCT06842823), the pivotal trial is testing the…
Deucrictibant, an experimental treatment for angioedema attacks, was well tolerated and effective in four patients with acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), according to a study. The proof-of-concept trial found that the “deucrictibant extended-release tablet effectively prevented angioedema attacks in patients with AAE-C1INH, with no safety concerns,”…
Late-treated and untreated swelling attacks in people with hereditary angioedema (HAE) are associated with a lower health-related quality of life and work productivity. That’s according to a U.S. study, which also found that as attack severity and time to treatment increased, patients’ quality of life and work productivity decreased.
The U.S. Food and Drug Administration (FDA) has approved donidalorsen — to be marketed Dawnzera — as a prophylactic treatment for swelling attacks in adults and adolescents, ages 12 and older, with hereditary angioedema (HAE). With this decision, Dawnzera has become the first and only RNA-targeted therapy approved for…
A woman in her 30s who experienced recurrent, nonspecific gastrointestinal symptoms was diagnosed with angioedema of the small intestine — also known as intestinal angioedema, or sometimes angioedema of the bowel — related to the use of an angiotensin-converting enzyme (ACE) inhibitor to treat high blood pressure, according to…
Navenibart, an experimental treatment from Astria Therapeutics to prevent swelling episodes in people with hereditary angioedema (HAE), continues to show strong and sustained benefits in a long-term clinical trial. New data from the ALPHA-SOLAR Phase 2 (NCT06007677) open-label extension study show treatment with navenibart every three…
The oral medication Orladeyo (berotralstat) is now approved in Colombia as a preventive treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval, from Colombia’s National Institute of Drug and Food Surveillance (INVIMA), follows the therapy’s approval in…
The prevalence of certain conditions — namely, allergies, autoimmune diseases, and asthma — is higher among people with hereditary angioedema (HAE) than in the general population, according to a new study from Canada. The data specifically showed that the proportion of HAE patients who reported having autoimmune conditions was…
A Phase 3 clinical trial testing sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE) has completed enrollment a year ahead of schedule. The trial’s initial target enrollment was surpassed in less than seven months, according to KalVista Pharmaceuticals, which is developing…
The symptoms of hereditary angioedema (HAE) can be very hard on adolescents, significantly affecting their health-related quality of life, particularly in regard to schooling and their social and emotional well-being, a U.S. study based on interviews with a dozen young patients reported. Those taking part, ages 12 to 17…
Get regular updates to your inbox.
